SAB Biotherapeutics Inc
NASDAQ:SABS 4:00:00 PM EDT
| Market Cap (Intraday) | 16.35M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.77 |
| 50-Day MA | $1.76 |
| 200-Day MA | $2.44 |
SAB Biotherapeutics Inc Stock, NASDAQ:SABS
777 West 41st Street, Suite 401, Miami Beach, Florida 33140
United States of America
Phone: +1.605.679.6980
Number of Employees: 57
Description
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.